Objectives: Children with severe-to-profound unilateral hearing loss, including cases of single-sided deafness (SSD), lack access to binaural cues that support spatial hearing, such as recognizing speech in complex multisource environments and sound source localization. Listening in a monaural condition negatively impacts communication, learning, and quality of life for children with SSD. Cochlear implant (CI) use may restore binaural hearing abilities and improve outcomes as compared to alternative treatments or no treatment. This study investigated performance over 24 months of CI use in young children with SSD as compared to the better hearing ear alone and to children with bilateral normal hearing (NH).
Design: Eighteen children with SSD who received a CI between the ages of 3.5 and 6.5 years as part of a prospective clinical trial completed assessments of word recognition in quiet, masked sentence recognition, and sound source localization at regular intervals out to 24-month postactivation. Eighteen peers with bilateral NH, matched by age at the group level, completed the same test battery. Performance at 24-month postactivation for the SSD group was compared to the performance of the NH group.
Results: Children with SSD have significantly poorer speech recognition in quiet, masked sentence recognition, and localization both with and without the use of the CI than their peers with NH. The SSD group experienced significant benefits with the CI+NH versus the NH ear alone on measures of isolated word recognition, masked sentence recognition, and localization. These benefits were realized within the first 3 months of use and were maintained through the 24-month postactivation interval.
Conclusions: Young children with SSD who use a CI experience significant isolated word recognition and bilateral spatial hearing benefits, although their performance remains poorer than their peers with NH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426784 | PMC |
| http://dx.doi.org/10.1097/AUD.0000000000001353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GH Therapy in Non-Growth Hormone-Deficient Children.
Children (Basel)
December 2024
Research Area for Innovative Therapy in Endocrinology, Bambino Gesù Children Hospital, IRCCS, 00165 Rome, Italy.
Before 1985, growth hormone (GH) was extracted from human pituitaries, and its therapeutic use was limited to children with severe GH deficiency (GHD). The availability of an unlimited amount of recombinant GH (rhGH) allowed for investigating the efficacy of its therapeutic use in a number of conditions other than GHD. Nowadays, patients with Turner syndrome, deficiency, Noonan syndrome, Prader-Willi syndrome, idiopathic short stature, chronic kidney disease, and children born small for gestational age can be treated with rhGH in order to improve adult height.
View Article and Find Full Text PDFPrevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study.
Haematologica
January 2025
For Anemia Foundation ETS, Genoa, Italy; Hematology Unit, IRCCS Giannina Gaslini, Genoa.
Not available.
View Article and Find Full Text PDFRethinking speech sound disorder (SSD) in non-syndromic cleft lip and palate: The importance of recognizing phonological and language difficulties.
Int J Lang Commun Disord
January 2025
School of Education, Communication and Language Sciences, Newcastle University, Newcastle upon Tyne, UK.
Background: Children born with cleft palate ± lip (CP ± L) are at risk of speech sound disorder (SSD). Up to 40% continue to have SSD at age 5-6 years. These difficulties are typically described as articulatory in nature and often include cleft speech characteristics (CSC) hypothesized to result from structural differences.
View Article and Find Full Text PDFDelayed Versus Atypical Speech Sound Development: A Markedness-Based Analysis of Speech Sound Disorder in Cantonese.
J Speech Lang Hear Res
January 2025
Division of Speech and Hearing Sciences, The University of Hong Kong, China.
Purpose: Speech sound disorder (SSD) is one of the major speech disorders in school-age children. Given the heterogeneity in terms of subtypes within SSD, there is a need to develop techniques for a quick identification of these subtypes. Furthermore, given the paucity of studies from children with SSD from Cantonese-speaking homes and a noted prevalence of SSDs in Cantonese-speaking children, it becomes even more important to investigate the subtypes of SSDs in Cantonese-speaking children.
View Article and Find Full Text PDFGenetic variants in COMT and ESR1 genes shape treatment response to raloxifene in schizophrenia-spectrum disorders.
Psychoneuroendocrinology
January 2025
Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.
Background/objective: Raloxifene, a selective estrogen receptor modulator (SERM), may improve symptoms and cognition in schizophrenia spectrum disorders (SSD). Studies have shown inconsistent efficacy, especially in men with SSD. We assessed whether single nucleotide polymorphisms (SNPs) on genes involved in the pharmacodynamics (ESR1 and COMT) and pharmacokinetics (UGT1A8) of raloxifene can explain the heterogeneous treatment response to raloxifene augmentation in patients with SSD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!